Anzeige
Mehr »
Login
Freitag, 23.07.2021 Börsentäglich über 12.000 News von 669 internationalen Medien
Das wird ja immer besser! Relay attackiert das 25-Milliarden-Ziel von zwei Seiten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W5SA ISIN: US9224751084 Ticker-Symbol: VEE 
Tradegate
23.07.21
15:36 Uhr
278,80 Euro
+0,10
+0,04 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
VEEVA SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
VEEVA SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
279,00279,6016:50
279,10279,8016:50
PR Newswire
228 Leser
Artikel bewerten:
(1)

Veeva Commercial Summit to Spotlight Digital Innovation at Leading Life Sciences Companies

Experts from Argenx, Boehringer Ingelheim, GSK, Regeneron, Sobi, and UCB to detail strategies for driving commercial agility

BARCELONA, Spain, June 1, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Boehringer Ingelheim, GSK, and UCB will be among the featured keynote speakers at the 2021 Veeva Commercial & Medical North America Summit Connect on June 10, 2021. They will share the innovative digital approaches and best practices helping their companies maximize commercial impact.

Veeva Systems

In a fireside chat opening the live online event, Dr. Cecil T. Holbert, M.D., a family medicine practitioner, and Amanda Romano, a diabetes business specialist at Boehringer Ingelheim, will discuss how digital-first engagement enables new ways of working and a better customer experience as healthcare provider (HCP) access evolves.

The event will also feature timely discussions around:

  • Advancing digital-first engagement - Raakhi Khera Sippy, vice president of global pharma marketing operations at GSK, will present a keynote on powering exceptional customer experiences with new digital content strategies. Sessions with Argenx, Merck, Novo Nordisk, Regeneron, Sanofi, and Sobi will also shed light on how digital has reinvented the commercial journey amidst the pandemic.
  • Powering data innovation for the future - In another keynote, Mamta Chhabra, global marketing lead for rare diseases at UCB, will highlight how her company is adapting to changes in media consumption and healthcare delivery by using data to better reach patients and their prescribers. Additionally, Chiasma, G1 Therapeutics, Oncopeptides, and Takeda will discuss the ways data-driven insights fuel more meaningful HCP connections and scientific exchange.

"In the past year, HCP expectations completely changed as the move to digital raised the bar for customer engagement," said Paul Shawah, executive vice president of strategy at Veeva. "This year's Summit Connect will showcase how innovative new digital-first models are transforming customer relationships."

Veeva Summit Connect is one of the largest gatherings for commercial leaders across life sciences to exchange ideas and connect with industry peers. Designed to maximize knowledge sharing through interactive sessions and roundtables, this year's event will feature more than 100 sessions from leaders changing the face of commercial in life sciences.

Life sciences industry professionals can learn more and register at veeva.com/Summit.

Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-K for the period ended January 31, 2021. This is available on the company's website at veeva.com under the Investors section and on the SEC's website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Contact:

Meagan Busath
Veeva Systems
925-452-6500
meagan.busath@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

VEEVA SYSTEMS-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.